dr. cathy eng discusses fresco-2 trial and fruquintinib for colorectal cancer
Published 1 year ago • 1.8K plays • Length 4:24Download video MP4
Download video MP3
Similar videos
-
9:41
dr. cathy eng discusses the fresco-2 study and its impact on metastatic colorectal cancer treatment
-
9:05
fresco-2: analyzing fruquintinib for refractory metastatic colorectal cancer
-
27:05
dr. cathy eng talks fruquintinib
-
4:48
fresco-2: phase iii study of fruquintinib in patients with mcrc
-
1:30
how will fruquintinib fit in the colorectal cancer treatment landscape?
-
56:17
2023 gi asco recap with dr. cathy eng
-
0:39
fda approval: #fruquintinib for #colorectalcancer
-
1:06:43
asco 2023 follow-up webinar with dr. cathy eng
-
2:27
fruquintinib in treating metastatic colorectal cancer
-
21:59
s2 episode 3: how do you treat refractory colorectal cancer?
-
3:58
dr. cathy eng on bevacizumab plus folfoxiri for patients with mcrc
-
19:34
dr. cathy eng (pt 2): controversies and open questions in gi oncology
-
1:19
targeted therapies for patients with her2 colorectal cancer
-
1:24
dr. eng on addressing unmet needs for colorectal cancer
-
4:42
volfi trial final results: mfolfoxiri and panitumumab versus folfoxiri in ecog 0-1 and primarily...
-
5:57
case studies in advanced colorectal cancer
-
2:21
cathy eng, md - anal cancer's first randomized trial for inoperable disease the treatment standard
-
1:07
targeting her2 in colorectal cancer
-
3:43
goals of therapy in refractory colorectal cancer